Matrix vesicles are extracellular organelles involved in mineral formation that are regulated by 1␣,25 (OH) 2 D 3 . Prior studies have shown that protein kinase C (PKC) activity is involved in mediating the effects of 1␣,25(OH) 2 D 3 in both matrix vesicles and plasma membranes. Here, we examined the regulation of matrix vesicle PKC by 1␣,25(OH) 2 D 3 during biogenesis and after deposition in the matrix. When growth zone costochondral chondrocytes were treated for 9 min with 1␣,25 (OH) 2 D 3 , PKC in matrix vesicles was inhibited, while PKC␣ in plasma membranes was increased. In contrast, after treatment for 12 or 24 h, PKC in matrix vesicles was increased, while PKC␣ in plasma membranes was unchanged. The effect of 1␣,25(OH) 2 D 3 was stereospecific and metabolite-specific. Monensin blocked the increase in matrix vesicle PKC after 24 h, suggesting the secosteroid-regulated packaging of PKC. In addition, the 1␣,25(OH) 2 D 3 membrane vitamin D receptor (1,25-mVDR) was involved, since a specific antibody blocked the 1␣,25(OH) 2 D 3 -dependent changes in PKC after both long and short treatment times. In contrast, antibodies to annexin II had no effect, and there was no evidence for the presence of the nuclear VDR on Western blots. To investigate the signaling pathways involved in regulating matrix vesicle PKC activity after biosynthesis, matrix vesicles were isolated and then treated for 9 min with 1␣,25(OH) 2 D 3 in the presence and absence of specific inhibitors. Inhibition of phosphatidylinositol-phospholipase C, phospholipase D, or G i /G s had no effect. However, inhibition of G q blocked the effect of 1␣,25(OH) 2 D 3 . The rapid effect of 1␣,25(OH) 2 D 3 also involved the 1,25-mVDR. Moreover, arachidonic acid was found to stimulate PKC when added directly to isolated matrix vesicles. These results indicate that matrix vesicle PKC is regulated by 1␣,25(OH) 2 D 3 at three levels: 1) during matrix vesicle biogenesis; 2) through direct action on the membrane; and 3) through production of other factors such as arachidonic acid.
. Moreover, the effect of 1␣,25(OH) 2 D 3 on PKC is blocked by Ab99, just as it is in the cell. However, 1␣,25(OH) 2 D 3 stimulates PKC activity in growth zone chondrocytes and when incubated directly with chondrocyte plasma membranes, whereas it inhibits PKC activity when incubated directly with matrix vesicles (19) , even though the same receptor is involved.
The purpose of the present study was to examine the mechanisms that regulate 1␣,25(OH) 2 D 3 -dependent PKC activity in matrix vesicles. There are several reasons why regulation of matrix vesicle PKC might differ from that of the plasma membrane. First, there is a differential distribution of PKC isoforms between the two membrane fractions. PKC predominates in matrix vesicles, whereas PKC␣ predominates in plasma membranes (19) . The two membrane fractions differ in other ways as well, including phospholipid composition (20) and basal membrane fluidity (3) .
Studies using chondrocytes from the resting zone of costochondral cartilage indicate that the responsive isoform in intact cells, as well as in isolated plasma membranes, is PKC␣, whereas the responsive isoform in matrix vesicles is PKC. Whether this is also the case for growth zone cells is not known, however. PKC is regulated by 24R,25(OH) 2 D 3 in resting zone cells, but 1␣,25(OH) 2 D 3 regulates activity in growth zone cells, and these two metabolites use two distinctly different mechanisms to regulate PKC activity in their target cells (9, 21) . Moreover, matrix vesicle composition, including phospholipids and enzyme activities, and regulation of matrix vesicle function differs between the two cell types (see Refs. 14, 22 for reviews).
It is likely that 1␣,25(OH) 2 D 3 regulates matrix vesicle PKC during organelle biogenesis, as well as directly, once they are resident in the extracellular matrix. When growth plate chondrocytes are cultured with 1␣,25(OH) 2 D 3 for 24 h, long enough for new gene expression and matrix vesicle synthesis, matrix vesicle PKC activity is increased (23) . While 1␣,25(OH) 2 D 3 has been shown to regulate the distribution of matrix proteinases in matrix vesicles (24) , it is not known if the increase in matrix vesicle PKC is due to preferential incorporation of specific isoforms of the enzyme. PKC␣ is sensitive to Ca 2ϩ ions and to phospholipid, whereas PKC is insensitive to both co-factors (25) , yet both Ca 2ϩ ions and phospholipid are present at relatively high levels in the growth plate extracellular matrix (26) , particularly in the growth zone. Thus, it is possible that other isoforms may be involved in the matrix vesicle response to 1␣,25(OH) 2 D 3 . For example, in renal epithelial cells, 1␣,25(OH) 2 D 3 has been shown to increase PKC␤ activity (27) . Other aspects of the signaling pathway by which 1␣,25(OH) 2 D 3 modulates matrix vesicle PKC may differ as well. G-protein, specifically G q but not G i or G s , mediates the effect of 1␣,25(OH) 2 D 3 on cellular PKC (21) ; whether this is the case for matrix vesicle PKC is unknown.
Phospholipid metabolism plays a major role in the mechanism of 1␣,25(OH) 2 D 3 -dependent PKC activity in the intact cell, causing rapid increases in phospholipase A 2 (PLA 2 ) and phospholipase C (PLC) activity, release of arachidonic acid and diacylglycerol, and production of prostaglandin E 2 (PGE 2 ) (9). This may not be the case for matrix vesicles, however. Matrix vesicles possess an active phospholipid metabolism that is regulated independently from that of the cell (28) . Their phospholipid composition is distinct from that of the plasma membrane as well (29 -31) . Unlike the plasma membrane, which has a phospholipid composition higher in phosphatidylcholine, matrix vesicles contain higher levels of phosphatidylserine and phosphatidylinositol, as well as cardiolipin. The basal fluidity of the plasma membrane and matrix vesicles also differs (3). Thus, it is likely that phospholipid metabolism may play a different role in the mechanism by which 1␣,25(OH) 2 -dependent isoform in each membrane fraction was determined using isoformspecific antibodies, comparing the effect at 90 min to the effect at 24 h. We also examined the regulation of matrix vesicle production by 1␣,25(OH) 2 D 3 using monensin to block protein transport through the Golgi. While it is known that the 1,25-mVDR mediates the rapid increase in PKC at 9 min (16), it is not known if the downstream genomic regulation of matrix vesicle PKC is also regulated via the 1,25-mVDR or any of the signaling pathways. The role of the 1,25-mVDR in the process was assessed using Ab99. We also examined whether the effect of 1␣,25(OH) 2 D 3 on matrix vesicle PKC at 24 h is mediated by PLC, which was previously shown to mediate the 1,25-mVDR-dependent rapid increase in PKC activity in growth zone cells. For these experiments, cells were treated with 1␣,25(OH) 2 D 3 in the presence of the phosphatidylinositol-specific (PI-PLC) inhibitor U73122.
The second model used matrix vesicles isolated from cultures not previously treated with 1␣,25(OH) 2 D 3 to examine the mechanism of the direct effect of the secosteroid. Matrix vesicles were incubated with 1␣,25(OH) 2 D 3 Ϯ inhibitors of signal transduction pathways shown previously to mediate the activation of PKC␣ in a number of experimental systems. For these experiments, membrane fractions were incubated with the following: U73122 to inhibit PI-PLC activity; cholera toxin, pertussis toxin, and GDP␤S to inhibit G-proteins; and wortmannin to inhibit phospholipase D (PLD). In addition, we examined the regulation of matrix vesicle PKC by agents shown previously to stimulate PKC␣ activity in growth zone cells. Matrix vesicles were treated directly with arachidonic acid, which is the product of PLA 2 action, the arachidonic acid precursor, linolenic acid, and the arachidonic acid metabolite PGE 2 as well as with diacylglycerol, the product of PLC action. The role of the 1,25-mVDR in the response of matrix vesicle PKC to 1␣,25(OH) 2 D 3 was assessed using Ab99. Specificity of the response was established using 1␤,25(OH) 2 D 3 and 24R,25(OH) 2 D 3 . The role of annexin II was assessed using antibodies to the C-terminal and N-terminal regions of the protein.
Because matrix vesicles do not contain DNA or RNA, any response to the addition of 1␣,25(OH) 2 D 3 by naive membranes would a priori be via nongenomic mechanisms. This would not rule out a role for the 1,25-nVDR, however. Accordingly, we examined matrix vesicles for the presence of the 1,25-nVDR by Western blot.
Reagents-Monensin and PGE 2 were purchased from Sigma. The following chemicals were purchased from Calbiochem (San Diego, CA): 1,2-dioctanoyl-sn-glycerol (DOG), arachidonic acid, linolenic acid, pertussis toxin (G i inhibitor), cholera toxin (G s inhibitor), GDP␤S (general G-protein inhibitor), and wortmannin (PLD inhibitor). 1␣,25(OH) 2 D 3 and 24R,25(OH) 2 D 3 were purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA). Recombinant nuclear vitamin D receptor (1,25-nVDR) was obtained from Affinity BioReagents, Inc., Golden, CO. Rabbit polyclonal anti-1,25-nVDR and alkaline phosphatase-conjugated anti-rabbit antibodies, as well as polyclonal rabbit antibodies specific for the ␣, ␤, ␦, ⑀, and isoforms of PKC, were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Nonspecific rabbit IgG1 was obtained from Sigma. Mouse monoclonal antibody to the C terminus of annexin II was obtained from Transduction Laboratories (Lexington, KY), and rabbit polyclonal antibody to the N terminus of annexin II was obtained from Santa Cruz Biotechnology. PKC assay reagents and Dulbecco's modified Eagle's medium were obtained from Life Technologies, Inc. (Gaithersburg, MD). The protein content of each sample was determined using the bicinchoninic acid protein assay reagent (32) obtained from Pierce. 1␤,25(OH) 2 D 3 was a generous gift from Dr. Anthony Norman, University of California, Riverside, CA.
Chondrocyte Cultures-The rat costochondral chondrocyte culture system used in this study has been described in detail previously (20) . Cells from the growth zone (prehypertrophic and upper hypertrophic cell zones) of costochondral cartilage from 125-g male Sprague-Dawley rats (Harlan, Indianapolis, IN) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, vitamin C, and antibiotics. Fourth passage cells were used for all experiments. The characteristics of these cells have been described in a number of publications and have been reviewed (14, 22) .
Membrane Isolation-Matrix vesicles were prepared by differential centrifugation of trypsin digests of the extracellular matrix as previously described (33) . In addition, plasma membranes were prepared by differential and sucrose gradient centrifugation of cells isolated from the same cultures for comparison.
Protein Kinase C-PKC activity was determined using previously described methods (19, 23) . To determine total PKC specific activity in each culture, cell layer lysates were used. To determine PKC specific activity of isolated matrix vesicles or plasma membranes, 10 g of membrane protein were diluted to a final volume of 35 l and assayed as described for the cell layer lysates. For experiments examining the direct effect of hormones and inhibitors on matrix vesicles and plasma membranes, the protein concentration was adjusted with 0.9% NaCl such that 10 g of membrane protein were incubated with the vitamin D 3 metabolites in a final volume of 50 l. Following incubation for the times shown below, 35 l was removed and assayed using the same conditions as for cell layer lysates.
To test the hypothesis that 1␣,25(OH) 2 D 3 modulates matrix vesicle PKC activity through production of new matrix vesicles and incorporation of PKC, confluent fourth passage cultures of growth zone chondrocytes were incubated with 10 Ϫ9 or 10 Ϫ8 M 1␣,25(OH) 2 D 3 for 0.2, 1.5, 12, and 24 h. At each time, plasma membranes and matrix vesicles were isolated from the cultures, and PKC specific activity was assayed. To determine whether the organelle-specific effect of 1␣,25(OH) 2 D 3 is due to a change in the differential distribution of PKC isoforms during matrix vesicle biogenesis, isoform-specific antibodies were used. Growth zone chondrocytes were treated with 10 Ϫ8 M 1␣,25(OH) 2 D 3 for 90 min or 24 h, and matrix vesicles and plasma membranes were isolated. Membranes were depleted of individual isoforms by immunoprecipitation, and the supernatant was assayed for remaining PKC activity (19) . Membrane preparations (10 g of protein/sample) were incubated on ice for 1 h with 6 l of a 1:10 dilution of nonspecific rabbit IgG1 or isoform-specific anti-PKC rabbit IgG1 in 0.9% saline, resulting in a final antibody dilution of 1:500. Protein G-agarose (10 l) (Oncogene Science, Inc., Uniondale, NY) was added for 4 h to clear the samples of immunoreactive PKC isoforms and any remaining unbound antibody. Following precipitation of this material, 35 l of the supernatant was assayed for PKC activity.
To determine whether protein transport through the Golgi apparatus is necessary for the PKC activity in matrix vesicles, growth zone chondrocyte cultures were treated for 24 h with 1-100 M monensin (34) . PKC activity was determined in matrix vesicles and plasma membranes as described above. To determine whether the long term effect of (37), it does not affect the rapid increase in PKC due to 1␣,25(OH) 2 D 3 in rat growth zone chondrocyte cultures (18) . Matrix vesicles were isolated from growth zone chondrocyte cultures that had been treated for 24 h with 10 Ϫ8 M 1␤,25(OH) 2 D 3 Ϯ Ab99. PKC activity was measured as described above. Specificity was also examined using 24R,25(OH) 2 D 3 , a metabolite of vitamin D that does not elicit a rapid increase in PKC in growth zone chondrocyte cultures (23), nor does it affect PKC when incubated with matrix vesicles or plasma membranes isolated from growth zone chondrocyte cultures (19) . For these studies, growth zone chondrocytes were treated with 10 Ϫ7 M 24R,25(OH) 2 D 3 Ϯ Ab99 for 24 h. Matrix vesicles were isolated, and PKC activity was determined.
To determine whether signaling pathways that mediate the rapid action of 1␣,25(OH) 2 D 3 on PKC in growth zone chondrocytes also mediate the downstream increase in matrix vesicle PKC, we examined the role of PI-PLC. Cultures were treated with 10 Ϫ8 M 1␣,25(OH) 2 D 3 Ϯ the inhibitor U73122 (0, 0.1, 1, or 10 M). Matrix vesicles were isolated, and PKC activity was determined.
Direct Action of 1␣,25(OH) 2 D 3 on Matrix Vesicle PKC-To determine whether the direct effect of 1␣,25(OH) 2 D 3 on PKC activity in matrix vesicles is also mediated by PI-PLC, matrix vesicles were incubated with 10 Ϫ8 M 1␣,25(OH) 2 D 3 alone, 10 M U73122 alone, or the two in combination for 3, 9, 30, or 90 min, and PKC activity was determined. In addition, we examined the direct effect of diacylglycerol (DAG) on matrix vesicle PKC. DAG is the product of PLC action; it is an activator of PKC in growth zone cells and mediates the rapid increase in PKC activity in response to 1␣,25(OH) 2 D 3 (38) . Matrix vesicles were incubated with 1, 10, or 100 M DOG for 9 min in the presence and absence of 10 Ϫ8 M 1␣,25(OH) 2 D 3 , and PKC activity was measured. DAG can also be produced through the action of PLD on phosphatidylcholine (39 1␣,25(OH) 2 D 3 Ϯ 0.1, 1, or 10 M wortmannin, a specific inhibitor of PLD activity (40, 41) . Wortmannin at higher concentrations can also inhibit PI 3-kinase (42); however, PI 3-kinase is not affected at the concentrations used in the present study (43) .
To determine whether 1␣,25(OH) 2 D 3 exerts its direct effects on matrix vesicle PKC through a G-protein-dependent mechanism, matrix vesicles were incubated for 9 min with 10 Ϫ8 M 1␣,25(OH) 2 D 3 in the presence of the general G-protein inhibitor GDP␤S (1, 10, or 100 M), cholera toxin to inhibit G s (1,10, or 100 M), or pertussis toxin to inhibit G i (1, 10, or 100 m).
The rapid effect of 1␣,25(OH) 2 D 3 on PKC in growth zone chondrocytes is mediated by the action of arachidonic acid (44) . In addition, linolenic acid, which is the precursor of arachidonic acid, also exerts a stimulatory effect on PKC activity in the cells, as does the arachidonic acid metabolite PGE 2 (45) . To determine whether one or more of these lipid mediators exerts an effect on matrix vesicle PKC, matrix vesicles were incubated with 1, 10, or 100 M arachidonic acid, 1, 10, or 100 M linolenic acid, or 0.015, 0.06, or 0.24 ng/ml PGE 2 We also determined if the direct effect of 1␣,25(OH) 2 D 3 on matrix vesicle PKC involves annexin II, which has been purported to be a receptor for this hormone in osteoblasts (46) . For these experiments, matrix vesicles isolated from growth zone chondrocyte cultures were treated with various dilutions of antibodies to the C terminus or N terminus of annexin II in the presence and absence of 10 Ϫ8 M 1␣,25(OH) 2 D 3 for 9 min. PKC specific activity was then assayed as described above.
1,25-nVDR-To determine whether the traditional 1,25-nVDR is present in matrix vesicles or plasma membranes, we examined matrix vesicles and plasma membranes from confluent fourth passage growth zone cell cultures by Western blot analysis after SDS-PAGE. In addition, we examined the cytosol/nuclear fraction obtained during plasma membrane purification. Isolated membranes and the cytosol/nuclear fraction were solubilized in sample buffer, and 20 g of protein was separated on 7.5% gradient acrylamide gels (47) . Blots of the gels were probed with anti-1,25-nVDR antibody (1:5000 dilution, Santa Cruz Biotechnology) or nonspecific IgG. Immunoreactive bands were visualized by an alkaline phosphatase-conjugated polyclonal anti-rabbit secondary antibody.
Statistical (Fig. 1A) . However, at 12 and 24 h, 1␣,25(OH) 2 D 3 dose dependently increased PKC activity in these organelles by 100% over control levels. In contrast, 1␣,25(OH) 2 D 3 affected plasma membrane PKC only at the early time points, causing a concentration-dependent increase in enzyme activity within 0.2 h (Fig. 1B) . Activity remained elevated at 1.5 h in cultures treated with 10 Ϫ8 M 1␣,25(OH) 2 D 3 , but by 12 h, specific activity had returned to control levels.
The predominant PKC isoform present in matrix vesicles was PKC. In control cultures at 90 min, anti-PKC antibody reduced activity by ϳ80%, whereas none of the other isoformspecific antibodies reduced activity ( Fig. 2A) . In cultures treated with 1␣,25(OH) 2 D 3 for 90 min, the anti-PKC antibody further reduced PKC specific activity to less than 10% of levels observed in cultures treated with IgG1, indicating that PKC was the 1␣,25(OH) 2 D 3 -sensitive isoform. At 24 h, the 1␣,25(OH) 2 D 3 -dependent increase in PKC activity was also due to PKC (Fig. 2B) . The anti-PKC antibody reduced 1␣,25(OH) 2 D 3 -stimulated PKC activity to below baseline levels, although levels still remained higher than in control cultures following precipitation of PKC with the isoform-specific antibody.
Regardless of the time point examined, the predominant PKC isoform present in plasma membranes was PKC␣ based on the reduction in enzyme activity following incubation with the anti-PKC␣ antibody (Fig. 3) . None of the other isoform-specific antibodies used caused a decrease in control cells. PKC␣ was also the isoform sensitive to 1␣,25(OH) 2 D 3 , based on the 70% reduction in total PKC specific activity in plasma membranes isolated from growth zone cells treated with the secosteroid for 90 min. However, the anti-PKC␣ antibodies did not completely reduce PKC activity to levels seen in control cells.
Incorporation of PKC activity in matrix vesicles was dependent upon protein transport through the Golgi. Treatment of the cultures for 24 h with monensin resulted in a dose-dependent decrease in matrix vesicle PKC specific activity (Fig. 4) . In contrast, PKC activity of the plasma membranes was unaffected by treatment of the cultures with monensin.
The stimulatory effect of 1,25(OH) 2 D 3 on matrix vesicle PKC was receptor-mediated. Not only was it stereospecific, but it 
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was metabolite-specific. Neither 1␤,25(OH) 2 D 3 nor 24R,25 (OH) 2 D 3 elicited the response (Fig. 5A) . Ab99 blocked the increase in matrix vesicle PKC due to 1␣,25(OH) 2 D 3 , but had no effect on PKC in control cultures or in cultures treated with 1␤,25(OH) 2 D 3 or 24R,25(OH) 2 D 3 , indicating that the 1,25-mVDR was involved.
Part of the long-term effect of 1␣,25(OH) 2 D 3 on matrix vesicle PKC involves a PI-PLC-dependent mechanism. U73122 caused a dose-dependent decrease in matrix vesicle PKC activity (Fig. 5B) . At the highest concentration of the PI-PLC inhibitor, there was a 30% reduction in the 1␣,25(OH) 2 D 3 -stimulated PKC activity.
The direct effect of 1␣,25(OH) 2 D 3 on PKC in isolated matrix vesicles was also mediated by the 1,25-mVDR. When matrix vesicles were incubated with 1␣,25(OH) 2 D 3 , Ab99 prevented the dose-dependent decrease in PKC activity, even at the highest concentration of the secosteroid (Fig. 6A) . Ab99 did not alter the 24R,25(OH) 2 D 3 -dependent decrease in PKC observed in matrix vesicles isolated from resting zone cell cultures (data not shown), indicating that the effect of the antibody was specific to the 1,25-mVDR and not due to a nonspecific interaction with the matrix vesicle or PKC. Moreover, Ab99 caused a dose-dependent reversal of the direct effect of 1␣,25(OH) 2 D 3 on matrix vesicle PKC, but increasing concentrations of Ab99 did not affect PKC activity of control matrix vesicles (Table I) . Furthermore, the direct effect of 1␣,25(OH) 2 D 3 on matrix vesicle PKC was not via annexin II. Antibodies to either the C or N terminus of the protein had no effect on 1␣,25(OH) 2 D 3 -dependent PKC inhibition, nor did they affect PKC activity of control matrix vesicles (Table I) .
PI-PLC was not involved in the 1␣,25(OH) 2 D 3 -dependent decrease in matrix vesicle PKC since U73122 did not alter the inhibitory effect of the secosteroid (Fig. 6B) . In addition, PKC in control matrix vesicles was not sensitive to PLC inhibition by U73122. Moreover, matrix vesicle PKC activity was insensitive to DOG, whether the organelles were treated with 1␣,25(OH) 2 D 3 or not (data not shown), indicating that diacylglycerol was not involved. The direct effect of 1␣,25(OH) 2 D 3 on matrix vesicle PKC was also not due to the action of PLD. Wortmannin did not alter enzyme activity in control matrix vesicles, nor did it reverse the inhibition of PKC due to 1␣,25(OH) 2 D 3 (data not shown).
1␣,25(OH) 2 D 3 mediates its direct effect on matrix vesicle PKC via a G-protein-dependent mechanism. Treatment of matrix vesicles with the general G-protein inhibitor GDP␤S resulted in an increase in PKC specific activity of control matrix vesicles and a reversal of the 1␣,25(OH) 2 D 3 -dependent decrease in PKC (Fig. 6C) . The G-protein responsible is neither G i nor G s , since cholera toxin and pertussis toxin had no effect on PKC activity of control or 1␣,25(OH) 2 D 3 -treated matrix vesicles (data not shown).
Matrix vesicle PKC was directly regulated by linolenic acid. Linolenic acid caused a rapid, dose-dependent increase in matrix vesicle PKC, whereas this fatty acid did not alter enzyme activity of isolated plasma membranes (Fig. 7A) . The increase in matrix vesicle PKC was time-dependent (Fig. 7B) . By 90 min, the direct effect on matrix vesicles was reduced by 30%. Even at 270 min, however, linolenic still exerted a stimulatory effect on matrix vesicle PKC compared with control matrix vesicles.
Arachidonic acid also directly regulated matrix vesicle PKC activity. In both control matrix vesicles and in matrix vesicles treated directly with 1␣,25(OH) 2 D 3 , arachidonic acid caused a rapid increase in PKC (Fig. 8A) . The effect of arachidonic acid 
was time-dependent (Fig. 8B ). Maximal increases in PKC were found in matrix vesicles incubated with arachidonic acid for 90 min. Moreover, only at this time point was the 1␣,25(OH) 2 D 3 -dependent decrease in PKC restored to control levels by arachidonic acid. In contrast to the stimulatory effects of linolenic acid and arachidonic acid on PKC specific activity, the arachidonic acid metabolite PGE 2 had no effect on enzyme activity in control matrix vesicles (data not shown). Similarly, PGE 2 did not alter the inhibitory effect of 1␣,25(OH) 2 D 3 . The direct effect of 1␣,25(OH) 2 D 3 on matrix vesicle PKC was not due to the nuclear VDR. Matrix vesicles and plasma membranes isolated from growth zone chondrocyte cultures contained no detectable immunoreactive 1,25-nVDR (Fig. 9) . The cytosol/nuclear fraction remaining after matrix vesicle and plasma membrane isolation did contain 1,25-nVDR immunoreactivity. Immunoreactive bands were seen at 63 and 297 kDa in the growth zone chondrocyte cytosol/nuclear fraction as compared with recombinant 1,25-nVDR, which was detected as a single band with a molecular mass of 63 kDa.
DISCUSSION
The results of this study indicate that 1␣,25(OH) 2 D 3 exerts its effects on matrix vesicle PKC activity through both direct and indirect mechanisms. The initial effect of the secosteroid is to cause the rapid decrease in existing matrix vesicle PKC activity by down-regulating PKC. It is likely that this is due to direct action of 1␣,25(OH) 2 D 3 on the matrix vesicle membrane. At later time points, however, 1␣,25(OH) 2 D 3 causes an increase in matrix vesicle PKC activity, suggesting that PKC is regulated at the time of matrix vesicle formation through genomic mechanisms.
The fact that monensin-treated cultures exhibit reduced PKC activity in their matrix vesicles, but not in their plasma membranes, indicates that less PKC is transported and packaged within matrix vesicles. This observation suggests that matrix vesicles are formed within the Golgi, independently of the plasma membrane. Studies using somatic cell hybrids to examine the role of alkaline phosphatase in osteoblasts demonstrated that alkaline phosphatase is packaged in matrix vesicles even when expression of the plasma membrane enzyme is extinguished (48) It is possible that the effect of Ab99 was directly on matrix vesicles already present in the extracellular matrix. However, it is more likely that it blocked the plasma membrane 1,25-mVDR since it inhibited the 1␣,25(OH) 2 D 3 -dependent increase in enzyme activity, which is cell-mediated.
Further evidence that the 1,25-mVDR is involved is the decrease in 1␣,25(OH) 2 D 3 -dependent matrix vesicle PKC noted in growth zone cells in the presence of U73122. This PI-PLC inhibitor also blocks the rapid effects of 1␣,25(OH) 2 D 3 on PKC activity that are mediated by the 1,25-mVDR in growth zone cells (23) . However, U73122 did not affect existing PKC activity in matrix vesicles incubated directly with the secosteroid, indicating that the changes in matrix vesicle PKC observed in cultures treated with 1␣,25(OH) 2 D 3 for 24 h were not due to direct effects of the secosteroid on existing matrix vesicles. Instead, they were due to indirect effects involving 1,25-mVDRdependent PKC synthesis and packaging in matrix vesicles through PLC-dependent signaling pathways, resulting in new PKC expression. Because the primary isoform active in matrix vesicles at 90 min and 24 h is PKC, the data suggest that PI-PLC activity is necessary for the production of PKC-enriched matrix vesicles rather than having a direct effect on existing matrix vesicle PKC. This is consistent with the matrix vesicle PKC being PKC because it is diacylglycerol-independent and would not require the production of diacylglycerol by PLC (25) . Similarly, DOG, a potent PKC-activating form of diacylglycerol, was shown in this study to be ineffective at activating matrix vesicle PKC activity when matrix vesicles were treated directly with the compound.
It is likely that MAP kinase was involved in the 1␣,25(OH) 2 D 3 -dependent increase in matrix vesicle PKC activity. 1␣,25(OH) 2 D 3 has been shown to mediate its effects on enterocytes (49) and osteoblasts (50) via MAP kinase signaling pathways, and the rapid increase in cellular PKC in response to 1␣,25(OH) 2 D 3 can result in increased MAP kinase activity (51) . Although 1␣,25(OH) 2 D 3 mediates many of its physiological effects on growth zone chondrocytes through mechanisms that include the 1,25-mVDR-dependent signaling pathways (17) , it is important to note that traditional 1,25-nVDR mechanisms are also likely to be involved in the packaging of matrix vesicle PKC in the present study. 1,25-nVDRs are present in the cells, as demonstrated by the presence of immunoreactive receptors in 
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Western blots of the cytosol/nuclear fraction of the growth zone chondrocytes. The dependence of the downstream increase in matrix vesicle PKC activity on the 1,25-mVDR suggests that the action of 1␣,25(OH) 2 D 3 on these two receptors is interrelated. 1␣,25(OH) 2 D 3 also exerts its direct effects on matrix vesicle PKC through receptor-mediated mechanisms. The 1,25-mVDR is involved since Ab99 reversed the 1␣,25(OH) 2 D 3 -dependent decrease in PKC activity. The 1,25-nVDR does not appear to play a role in the direct action of 1␣,25(OH) 2 D 3 on matrix vesicles, however. We failed to identify the 1,25-nVDR on Western blots of either the matrix vesicles or plasma membranes isolated from growth zone chondrocyte cultures, although it was present in the cytosol/nuclear fraction of these cells.
Annexin II has also been reported to be a membrane receptor for 1␣,25(OH) 2 D 3 (46) , and annexin II is present in matrix vesicles produced by chick growth plate chondrocytes (52) and osteoblast-like cells (53) . It is unlikely that annexin II is responsible for the 1␣,25(OH) 2 D 3 -dependent effects on matrix vesicles, however. Antibodies to annexin II failed to block the direct inhibition of matrix vesicle PKC by 1␣,25(OH) 2 D 3 . This confirms our earlier observation using osteoblast cell lines (53). Ab99 did not cross react with annexin II in Western blots of matrix vesicles produced by osteoblast cultures, nor did antibodies to annexin II block the 1␣,25(OH) 2 D 3 -dependent increase in PKC in these cells.
The mechanism by which 1␣,25(OH) 2 D 3 regulates matrix vesicle PKC are different from those that mediate the regulation of cellular PKC. PI-PLC is not involved, nor is diacylglycerol. PLD is also not involved, based on the lack of an effect of wortmannin either on PKC activity of control matrix vesicles or on PKC activity of 1␣,25(OH) 2 D 3 -treated matrix vesicles. In contrast, both cellular PKC and matrix vesicle PKC are regulated by G-protein-dependent mechanisms. As noted for intact cells (38) , neither G s nor G i is involved, either in maintenance of PKC activity in control matrix vesicles or in the decrease noted in matrix vesicles treated with 1␣,25(OH) 2 D 3 . However, inhibition of G-protein activity with GDP␤S blocks the effects of 1␣,25(OH) 2 D 3 . Thus, G q is the likely candidate because it is not sensitive to pertussis toxin or cholera toxin (54) . This is the case for intact cells as well (21) .
1␣,25(OH) 2 D 3 causes an increase in matrix vesicle phospholipase A 2 activity (28), suggesting that release of arachidonic acid might be involved in the mechanism of its action on matrix vesicle PKC. However, the direct effect of 1␣,25(OH) 2 D 3 is a decrease in PKC activity, and exogenous arachidonic acid elicits a rapid increase. Others have noted that arachidonic acid can stimulate PKC directly, particularly the PKC␣ isoform (55) , explaining in part how this fatty acid can increase PKC activity in growth zone chondrocyte cultures (44) . It is likely that arachidonic acid did not cause an increase in PKC activity of the isolated matrix vesicles because PKC is relatively insensitive to the fatty acid (56) . It is more likely that arachidonic acid is exerting its stimulatory effect on the low levels of PKC␣ present in the organelles (19) .
One way the chondrocytes might be able to activate matrix vesicle PKC activity after the matrix vesicles are formed and released into the extracellular matrix would be to secrete a regulatory factor that could act remotely on the organelles. We have shown that 1,25(OH) 2 If anything, the stimulatory effect of linolenic acid on matrix vesicle PKC activity is even more robust than the effect of its metabolite, arachidonic acid. Moreover, the effect of linolenic acid is specific to matrix vesicles; when plasma membranes were incubated directly with this fatty acid, no change in PKC activity was observed. Linolenic acid has been shown to be a potent activator of PKC (56) . The significance of this is unclear at this time.
In contrast to the stimulatory effects of arachidonic acid and its biosynthetic precursor linolenic acid, the arachidonic acid metabolite PGE 2 had no effect on matrix vesicle PKC. In intact cultures, PGE 2 mediates the stimulatory effects of 1␣,25(OH) 2 D 3 on PKC␣ through its action on EP1 receptors (18) . Whether EP1 is also present in matrix vesicles is not yet known, nor is it known if matrix vesicles contain cyclooxygenase activity. Fig. 10 illustrates our current model of 1␣,25(OH) 2 D 3 regulation of matrix vesicle PKC activity. 1␣,25(OH) 2 D 3 binds to the 1,25-mVDR on the plasma membrane, triggering the production of matrix vesicles containing increased PKC activity through genomic mechanisms mediated by PKC and MAP kinase as well as by the 1,25-nVDR. PLA 2 activity is also increased, generating arachidonic acid, which acts on matrix vesicles in the extracellular matrix, increasing PKC activity. In addition, 1␣,25(OH) 2 D 3 acts directly on matrix vesicles, activating the 1,25-mVDR and causing a rapid decrease in PKC activity through a mechanism involving G q . The combination of an increase in PKC␣ and a decrease in PKC modulates activity of matrix metalloproteinases present in the matrix vesicles (58), leading to growth factor activation, matrix remodeling, maturation, calcification, and endochondral ossification (8, 24, 59) .
In summary, these results show that the 1,25-mVDR is present in matrix vesicles from growth zone chondrocytes, whereas the 1,25-nVDR is not. 1␣,25(OH) 2 mVDR in growth zone cells results in an increase in production of new matrix vesicles that are enriched in PKC through a mechanism involving PI-PLC. In matrix vesicles, 1␣,25 (OH) 2 D 3 mediates its 1,25-mVDR-dependent effects on PKC through a mechanism that involves G q but not PI-PLC or PLD. Matrix vesicle PKC is also stimulated by arachidonic acid and linolenic acid, suggesting additional pathways for modulating the activities of the extracellular organelles. These findings demonstrate that matrix vesicles are unique organelles that can be differentially regulated at the time of their production and at sites distant from the cell surface, either through direct action of 1␣,25(OH) 2 D 3 or by regulatory factors such as arachidonic acid. This demonstrates the complexity of the role of 1␣,25(OH) 2 D 3 in chondrocyte biology and indicates that 1␣,25(OH) 2 D 3 acts both through nuclear and membrane receptors to regulate the biomineralization processes.
